|
|
|
|
RNA therapeutics and vaccines are revolutionizing medicine, with in vitro transcription (IVT) using T7 polymerase at the heart of their production. While wild-type T7 polymerases offer reliability, engineered variants are redefining performance with higher yields and lower impurities.
|
|
|
|
|
Lipid nanoparticles (LNPs) typically comprise four lipids, with the ionizable lipid being crucial for nucleic acid encapsulation and release. The choice of mixing method — either laminar or turbulent — significantly affects the critical quality attributes of the final product.
|
|
|
|
|
High costs and lengthy timelines slow xRNA therapy development. See how a continuous manufacturing platform streamlines production to just days, utilizes real-time quality control, and dramatically cuts costs to accelerate access to new therapies.
|
|
|
|
|
Explore how a partnership between academia, regulatory agencies, and manufacturing organizations has the potential to reshape the way we produce and distribute mRNA-based therapies.
|
|
|
|
|
Watch this webinar to explore the transformative potential of PAT in mRNA manufacturing, including how predictive models monitor key critical quality attributes (CQAs) like RNA concentration and nucleoside triphosphate consumption.
|
|
|
|
|
|
RNA Therapies
|
One Team, One Roof, One CDMO
Recipharm’s expanded biologics services and technologies encompass the entire RNA development and manufacturing value chain, helping to deliver your innovation to patients seamlessly.
|
|
• Request Information
|
|
|
|
|
|
|
|
